Law360, New York (November 18, 2008, 12:00 AM ET) -- The U.S. Department of Justice is investigating Medtronic Inc. over the possible marketing of the medical company's spinal graft product for purposes that have not been approved by the U.S. Food and Drug Administration.
Medtronic chief executive Bill Hawkins revealed on an investor conference call Tuesday that the company had recently received a subpoena from the DOJ regarding off-label use of its Infuse Bone Graft product, which the FDA warned in July could cause serious complications in neck-bone fusion procedures, Dow Jones reported Tuesday.
Hawkins said...
DOJ Subpoenas Medtronic Over Bone Graft Product
To view the full article, take a free trial now.
